Colony-stimulating factors in the treatment of HIV-associated non-Hodgkin's lymphoma.
Treatment results using standard chemotherapeutic regimens for patients with intermediate and high-grade non-Hodgkin's lymphoma have been disappointing. For patients with HIV-associated lymphoma, whose bone marrow tolerance is so limited, conservative dose combination chemotherapy has been the only realistic option. Now, however, the availability of recombinant colony-stimulating factors allows more dose-intensive therapy to be used. Both recombinant human granulocyte colony-stimulating factor and recombinant human granulocyte macrophage colony-stimulating factor have undergone Phase I testing and have been shown to reduce bone marrow toxicity following combination chemotherapy in non-HIV-infected patients. While this may be a promising lead for the treatment of HIV-infected patients also, it must be noted that until randomized trials are performed, no clear effects on survival or response can be verified.
Walsh
C
C
Division of Oncology, Kaplan Cancer Center, New York University.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003115:Colony-Stimulating Factors / Q000627:therapeutic use*; D004341:Drug Evaluation; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D006133:Growth Substances / Q000627:therapeutic use*; D015658:HIV Infections / Q000150:complications*; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000209:etiology; D011994:Recombinant Proteins / Q000627:therapeutic use
D003115:Colony-Stimulating Factors; D006133:Growth Substances; D011994:Recombinant Proteins; D016178:Granulocyte-Macrophage Colony-Stimulating Factor